Spontaneous adult height in idiopathic short stature
- PMID: 8522275
- DOI: 10.1159/000184616
Spontaneous adult height in idiopathic short stature
Abstract
Two hundred and thirty-six patients with idiopathic short stature (ISS) (184 m, 52 f) who presented at a mean age of 12.2 (range 2.8-17.5) years, a mean height of -2.16 standard deviation score (SDS), a mean target height (THT) of -0.27 SDS (m = f), were reinvestigated at a mean age of 20.5 (range 18-24) years. 182(142 m, 37 f) (67%) had reached normal adult height (AHT) while 54 (39 m, 15 f) (23%) had not. However, only 23 (17 m, 6 f) did not reach a height within their familial target. Patients were subdivided into 2 groups according to deviation from familial height target: 60(44 m, 16 f) were considered adequate for their families (group 1), while 176 (140 m, 39 f) were smaller (group 2). Children in group 1 were younger and bone age (BA) was less retarded. Patients in group 1 reached their THT, this was not the case in group 2. Young age, low THT and low predicted adult height (PAH) at presentation were the factors associated with poor stratural outcome, but AHT could not be predicted in individuals. In boys, PAH (Bayley-Pinneau) (0.0 SDS) exceeded AHT (-0.7 SDS), in girls, both were almost identical (-0.79, -0.77 SDS). Since most children with ISS reach an AHT within the normal range, attempts to improve AHT by means of growth-promoting therapies appear to be justified only in a minority of selected patients with ISS. Methods to improve the accuracy of individual height prognoses are needed.
Similar articles
-
Combined therapy with GnRH analogue and growth hormone increases adult height in children with short stature and normal pubertal onset.Endocrine. 2020 Sep;69(3):615-624. doi: 10.1007/s12020-020-02375-5. Epub 2020 Jun 12. Endocrine. 2020. PMID: 32533506
-
Growth hormone treatment of idiopathic short stature.Horm Res. 1996;46(4-5):208-14. doi: 10.1159/000185025. Horm Res. 1996. PMID: 8950623 Review.
-
Natural history of idiopathic advanced bone age diagnosed in childhood: pattern of growth and puberty.Horm Res Paediatr. 2011;75(1):49-55. doi: 10.1159/000319315. Epub 2010 Sep 2. Horm Res Paediatr. 2011. PMID: 20814190
-
A pilot study of growth hormone administration in boys with predicted adult short stature and near-ending growth.Growth Horm IGF Res. 2015 Apr;25(2):96-102. doi: 10.1016/j.ghir.2015.01.002. Epub 2015 Jan 26. Growth Horm IGF Res. 2015. PMID: 25641639 Clinical Trial.
-
Growth in disorders of adrenal hyperfunction.Horm Res. 2002;58 Suppl 1:39-43. doi: 10.1159/000064767. Horm Res. 2002. PMID: 12373013 Review.
Cited by
-
The use of somatropin (recombinant growth hormone) in children of short stature.Paediatr Drugs. 2002;4(1):37-47. doi: 10.2165/00128072-200204010-00005. Paediatr Drugs. 2002. PMID: 11817985 Review.
-
Spontaneous growth in idiopathic short stature. European Study Group.Arch Dis Child. 1996 Sep;75(3):175-80. doi: 10.1136/adc.75.3.175. Arch Dis Child. 1996. PMID: 8976652 Free PMC article.
-
Treatment of children and adolescents with idiopathic short stature.Nat Rev Endocrinol. 2013 Jun;9(6):325-34. doi: 10.1038/nrendo.2013.71. Epub 2013 Apr 23. Nat Rev Endocrinol. 2013. PMID: 23609338 Review.
-
Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit.Int J Pediatr Endocrinol. 2014;2014(1):15. doi: 10.1186/1687-9856-2014-15. Epub 2014 Jul 16. Int J Pediatr Endocrinol. 2014. PMID: 25075207 Free PMC article.
-
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection.Biologics. 2010 Jun 24;4:147-55. doi: 10.2147/btt.s6363. Biologics. 2010. PMID: 20631818 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical